Ironwood Pharmaceuticals
IRWD
151 hedge funds and large institutions have $2.69B invested in Ironwood Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 44 increasing their positions, 52 reducing their positions, and 17 closing their positions.
105% more call options, than puts
Call options by funds: $21.8M | Put options by funds: $10.7M
24% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 17
7.57% more ownership
Funds ownership: 117.19% → 124.76% (+7.6%)
2% more funds holding
Funds holding: 148 → 151 (+3)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
6% less capital invested
Capital invested by funds: $2.85B → $2.69B (-$157M)
15% less repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 52
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BM
Bridger Management
New York
|
+$11.7M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$9.44M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$9.44M |
| 4 |
Westfield Capital Management
Boston,
Massachusetts
|
+$9.18M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$8.98M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$42.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$22.1M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$20.9M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$19.8M |
| 5 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$18.2M |
IRWD Hedge Fund Activity: Q3 2018 in Review
151 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q3 2018, worth a combined $2.69B — down 5.5% from $2.85B a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new IRWD positions and 17 closed out — a net gain of 4 holders — while 44 added to existing stakes and 52 trimmed.
The largest buyer was Bridger Management, opening a new position worth an estimated $11.7M. The largest seller was T. Rowe Price Associates, cutting an estimated $42.4M.
- 151 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q3 2018, up from 148 in Q2 2018.
- Funds reported $2.69B of Ironwood Pharmaceuticals stock for Q3 2018, down 5.5% quarter-over-quarter.
- 21 funds opened new Ironwood Pharmaceuticals positions in Q3 2018 and 17 closed out, a net change of +4 holders.
- The largest Ironwood Pharmaceuticals buyer in Q3 2018 was Bridger Management, an estimated $11.7M added.
- The largest Ironwood Pharmaceuticals seller in Q3 2018 was T. Rowe Price Associates, an estimated $42.4M sold.
Based on aggregated 13F filings for Q3 2018.